<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix’ VeriStrat Test Now Covered By Humana, Medical Mutual of Ohio, PreferredOne

    Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)

    AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab

    Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.

    Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

    Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)

    More Information on Disease State and Trial Options for Patients with Advanced Non-Small Cell Lung Cancer; Evaluating Automated and Manual Workflows in cfDNA Extraction

    Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.

    Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry

    Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC

    Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

    CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.

    Biodesix® and Progenetics Announce Distribution Agreement for Israel

    Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.

    Biodesix Closes Series E Financing

    Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.

    Biodesix and Capital Royalty Close Financing Transaction

    Biodesix has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.

    Biodesix Adds to Series E Financing

    Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.

    1 2 3 4 5